Compare · BDMD vs DXCM
BDMD vs DXCM
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.57B, about 674.0x BDMD ($49.8M).
- Over the past year, BDMD is down 53.0% and DXCM is up 16.5% - DXCM leads by 69.5 points.
- DXCM has been more active in the news (9 items in the past 4 weeks vs 7 for BDMD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- DexCom Inc.
- Price
- $1.18+0.43%
- $88.96-0.22%
- Market cap
- $49.8M
- $33.57B
- 1M return
- +12.44%
- +18.84%
- 1Y return
- -53.00%
- +16.50%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 7
- 9
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BDMD
- Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
- SEC Form 424B3 filed by Baird Medical Investment Holdings Ltd
- SEC Form EFFECT filed by Baird Medical Investment Holdings Ltd
- SEC Form EFFECT filed by Baird Medical Investment Holdings Ltd
- Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally
- SEC Form POS AM filed by Baird Medical Investment Holdings Ltd
- Amendment: SEC Form F-3/A filed by Baird Medical Investment Holdings Ltd
- SEC Form SCHEDULE 13D filed by Baird Medical Investment Holdings Ltd
- New insider Excelfin Spac Llc claimed ownership of 7,004,016 units of Ordinary shares (SEC Form 3)
- Amendment: SEC Form 20-F/A filed by Baird Medical Investment Holdings Ltd
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.